$2.42
4.35%
Nasdaq, Fri, Sep 06 2024
ISIN
US98973P1012
Symbol
ZIOP
Sector
Industry

ZIOPHARM Oncology, Inc. Stock price

$2.42
-0.02 0.97% 1M
-16.38 87.13% 6M
-8.19 77.18% YTD
-16.98 87.52% 1Y
-245.08 99.02% 3Y
-684.58 99.65% 5Y
-482.08 99.50% 10Y
Nasdaq, Closing price Fri, Sep 06 2024
-0.11 4.35%
ISIN
US98973P1012
Symbol
ZIOP
Sector
Industry

Key metrics

Market capitalization $3.88m
Enterprise Value $1.42m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 142.00
P/S ratio (TTM) P/S ratio 388.00
P/B ratio (TTM) P/B ratio 1.03
Revenue growth (TTM) Revenue growth -99.79%
Revenue (TTM) Revenue $10.00k
EBIT (operating result TTM) EBIT $-13.50m
Free Cash Flow (TTM) Free Cash Flow $-17.36m
Cash position $2.46m
EPS (TTM) EPS $-11.95
P/E forward negative
Short interest 16.91%
Show more

Is ZIOPHARM Oncology, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

ZIOPHARM Oncology, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

2 Analysts have issued a ZIOPHARM Oncology, Inc. forecast:

2x Hold
100%

Analyst Opinions

2 Analysts have issued a ZIOPHARM Oncology, Inc. forecast:

Hold
100%

Financial data from ZIOPHARM Oncology, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
0.01 0.01
100% 100%
100%
- Direct Costs 1.31 1.31
65% 65%
13,100%
-1.30 -1.30
63% 63%
-13,000%
- Selling and Administrative Expenses 6 6
21% 21%
60,000%
- Research and Development Expense 4.90 4.90
81% 81%
49,000%
-12 -12
61% 61%
-121,900%
- Depreciation and Amortization 1.31 1.31
65% 65%
13,100%
EBIT (Operating Income) EBIT -14 -14
61% 61%
-135,020%
Net Profit -19 -19
48% 48%
-191,300%

In millions USD.

Don't miss a Thing! We will send you all news about ZIOPHARM Oncology, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

ZIOPHARM Oncology, Inc. is a biopharmaceutical company, which engages in the development, acquisition, and commercialization of immuno-oncology platforms that leverage cell- and gene-based therapies to treat patients with cancer. Its pipeline include Sleeping Beauty TCR-T Targeting neoantigens; Ad-RTS-hlL-12 + veledimex; and Sleeping Beauty CAR-T. The company was founded on September 9, 2003 and is headquartered in Boston, MA.

Head office United States
CEO Dale Hogue
Employees 1
Founded 2003
Website www.alaunos.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today